XENON PHARMACEUTICALS INC. (NASDAQ:XENE) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02
XENON PHARMACEUTICALS INC. (NASDAQ:XENE) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Xenon Pharmaceuticals Inc. Exhibit
EX-10.1 2 xene-ex101_24.htm EX-10.1 xene-ex101_24.htm Exhibit 10.1 AMENDED AND RESTATED 2014 EQUITY INCENTIVE PLANXENON PHARMACEUTICALS INC. (as amended April 16,…
To view the full exhibit click here
About XENON PHARMACEUTICALS INC. (NASDAQ:XENE)
Xenon Pharmaceuticals Inc. (Xenon) is a biopharmaceutical company discovering and developing a pipeline of differentiated therapeutics for orphan indications. The Company’s platform, Extreme Genetics, enables the discovery of validated drug targets by studying rare human diseases with extreme traits, including diseases caused by mutations in ion channels (channelopathies). Extreme Genetics involves the study of families where individuals exhibit inherited severe traits, or phenotypes. Its integrated platform includes in-house capabilities for human genetics, small molecule drug discovery, as well as preclinical and clinical development. Its pharmaceutical partners include Teva Pharmaceutical Industries, Ltd. (Teva), Genentech, Inc. (Genentech) and Merck & Co., Inc. (Merck). Extreme Genetics discovery platform has yielded the first approved gene therapy product in the European Union, or the EU, and a development pipeline, including Glybera, TV-45070, GDC-0276 and GDC-0310, and XEN801.
